Venclexta (venetoclax)

pCPA File Number: 21375

Negotiation Status:

Concluded with an LOI

Indication(s):

Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible

Sponsor/Manufacturer:

AbbVie Corporation

CADTH Project Number:

PC0212

pCPA Engagement Letter Issued:

2021-02-23

Negotiation Process Concluded:

2021-10-13